Cardiac Enzymes, Renal Failure and Renal Transplantation

Bozbaş, Hüseyin; Yildirir, Aylin; Müderrisoğlu, Haldun

doi:10.3121/cmr.4.1.79

Cited by 21 publications

(15 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic kidney disease, with its resulting renal dysfunction, is associated with excessive cardiovascular mortality, especially in those patients receiving renal replacement therapy (66 ). Prevalence of CVD in patients with chronic renal failure (CRF) is up to 73% and is responsible for approximately half of all CRF-related deaths (67 ).…”

Section: Renal Dysfunctionmentioning

confidence: 99%

“…Prevalence of CVD in patients with chronic renal failure (CRF) is up to 73% and is responsible for approximately half of all CRF-related deaths (67 ). In patients with a functioning kidney allograft, CVD is the most common cause of death (66 ). Atypical presentation of ACS (often without angina) and silent ischemia occur with increased frequency in patients with CRF; interpretation of the ECG in these patients can be complicated by the presence of left ventricular hypertrophy, electrolyte derangement, conduction abnormalities, and medications (67 ).…”

Section: Renal Dysfunctionmentioning

confidence: 99%

See 1 more Smart Citation

Increases of Cardiac Troponin in Conditions other than Acute Coronary Syndrome and Heart Failure

2009

View full text Add to dashboard Cite

Background: Although cardiac troponin (cTn) is a cornerstone marker in the assessment and management of patients with acute coronary syndrome (ACS) and heart failure (HF), cTn is not diagnostically specific for any single myocardial disease process. This narrative review discusses increases in cTn that result from acute and chronic diseases, iatrogenic causes, and myocardial injury other than ACS and HF.Content: Increased cTn concentrations have been reported in cardiac, vascular, and respiratory disease and in association with infectious processes. In cases involving acute aortic dissection, cerebrovascular accident, treatment in an intensive care unit, and upper gastrointestinal bleeding, increased cTn predicts a longer time to diagnosis and treatment, increased length of hospital stay, and increased mortality. cTn increases are diagnostically and prognostically useful in patients with cardiac inflammatory diseases and in patients with respiratory disease; in respiratory disease cTn can help identify patients who would benefit from aggressive management. In chronic renal failure patients the diagnostic sensitivity of cTn for ACS is decreased, but cTn is prognostic for the development of cardiovascular disease. cTn also provides useful information when increases are attributable to various iatrogenic causes and blunt chest trauma.Summary: Information on the diagnostic and prognostic uses of cTn in conditions other than ACS and heart failure is accumulating. Although increased cTn in settings other than ACS or heart failure is frequently considered a clinical confounder, the astute physician must be able to interpret cTn as a dynamic marker of myocardial damage, using clinical acumen to determine the source and significance of any reported cTn increase.

show abstract

Section: Renal Dysfunctionmentioning

confidence: 99%

Section: Renal Dysfunctionmentioning

confidence: 99%

Increases of Cardiac Troponin in Conditions other than Acute Coronary Syndrome and Heart Failure

2009

View full text Add to dashboard Cite

show abstract

“…4,5 Those patients whopresentedlate or with evidence of liverdisease, chronic kidney disease, and those suspected to have pulmonary thromboembolism were excluded from present study. 6 The recruited patients after signing the informed consent underwent a series of investigations such as Electrocardiography, Random blood sugar, Urea, Creatinine, liver function test estimation of cardiac biomarkers such as CK-MB, cardiac Troponin I (cTnI) using electro chemiluminescence immunoassay-2 antibodies sandwich principleand H-FABP by Enzyme Linked Immune Sorbent Assay (ELISA), based on biotin double antibody sandwich technology.…”

Section: Methodsmentioning

confidence: 99%

Diagnostic utility of heart type fatty acid binding protein (H-FABP) versus cardiac troponin I in myocardial infarction

et al. 2018

View full text Add to dashboard Cite

Background: Acute myocardial infarction (AMI) management is one of the therapeutic challenges faced by the emergency physician. In the field of investigational cardiology advancements, the search of superior cardiac biomarkers has led to the discovery of sensitive biomarkers which help in the early confirmation of MI as timely intervention is the primary goal in acute coronary syndrome (ACS). Present study was aimed to evaluate the diagnostic performance of the novel biomarker H- FABP in patients with AMI especially in ST elevation MI (STEMI) and comparison of its diagnostic accuracy with the other biomarkers.Methods: We studied 66 patients with persistent STEMI presenting within 12 hours of symptom to the department of General Medicine, Sri Manakula Vinayagar Medical College and Hospital (SMVMCH), Puducherry. Quantitative and qualitative estimation and analysis of serum biomarkers of acute myocardial infarction such as CK-MB, cardiac Troponin I (cTnI) and H-FABP were done.Results: The sensitivity and specificity of H-FABP were 80.7 and 88.9% respectively. The positive percentage of the serum biomarkers among these patients were 64%, 65%, 86% for CK-MB, cardiac troponin I, and H-FABP respectively. The area under the curve was observed to be 0.695, with 95% confidence interval (0.514-0.876) at the optimum cut-off value of 7.0ng/ml for H-FABP.Conclusions: H-FABP the novel biomarker, because of its early appearance in the blood stream and due to its superior sensitivity and specificity compared to Troponin I and CK-MB can be used in the early diagnosis of acute ST elevation Myocardial Infarction.

show abstract

“…The reasons for this remain unclear. Possible mechanisms include coronary artery disease, left ventricular dysfunction, left ventricular hypertrophy, cardiac microinfarctions and arrhythmia [6,7]. Non-ischemic myocardial injury due to uremic toxins, may be re-expression of fetal Troponin-T in myopathic skeletal muscles [7].…”

Section: Introductionmentioning

confidence: 99%

“…Possible mechanisms include coronary artery disease, left ventricular dysfunction, left ventricular hypertrophy, cardiac microinfarctions and arrhythmia [6,7]. Non-ischemic myocardial injury due to uremic toxins, may be re-expression of fetal Troponin-T in myopathic skeletal muscles [7]. The Food and Drug Administration recently approved the use of cTnT as a biomarker for mortality risk stratification in ESRD, and the use of cTnT for prognostication is also recommended by the Kidney Disease Outcomes Quality Initiative (KDOQI) [8].…”

Section: Introductionmentioning

confidence: 99%

Role of novel cardiac biomarkers in prediction of cardiovascular risk in predialysis CKD patients by their correlations with left ventricular mass index

Sathi¹,

Sunder²,

Mahapatra³

et al. 2014

Clin Nephrol Urol Sci

View full text Add to dashboard Cite

Background: Cardiac biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac troponin T (cTnT), hsCRP and Albuminuria, predicts underlying heart disease in the general population as well as in CKD patients. Objective: To study association of NT-proBNP, cTnT, hsCRP, spot urine albumin creatinine ratio with left ventricular mass index (LVMI) for cardiovascular risk prediction in predialysis CKD patients. Methods: Cross section study included a total of 120 adult predialysis CKD patients. 40 patients in each predialysis CKD group of stage 3, 4 and 5 were taken. Serum cTnT, serum hsCRP, plasma NT-proBNP, single spot urine albumin creatinine ratio (UACR) were measured. Two-dimensional targeted M-mode Echocardiography was done to measure left ventricular mass index (LVMI). Results: Mean values of Plasma NT-proBNP (pg/ml), Serum hs-CRP (mg/L), Spot UACR (mg/g of creatinine) and LVMI (g/m

show abstract

Cardiac Enzymes, Renal Failure and Renal Transplantation

Cited by 21 publications

References 47 publications

Increases of Cardiac Troponin in Conditions other than Acute Coronary Syndrome and Heart Failure

Increases of Cardiac Troponin in Conditions other than Acute Coronary Syndrome and Heart Failure

Diagnostic utility of heart type fatty acid binding protein (H-FABP) versus cardiac troponin I in myocardial infarction

Role of novel cardiac biomarkers in prediction of cardiovascular risk in predialysis CKD patients by their correlations with left ventricular mass index

Contact Info

Product

Resources

About